Literature DB >> 19250656

Prevalence of fibromyalgia: a survey in five European countries.

Jaime C Branco1, Bernard Bannwarth, Inmaculada Failde, Jordi Abello Carbonell, Francis Blotman, Michael Spaeth, Fernando Saraiva, Francesca Nacci, Eric Thomas, Jean-Paul Caubère, Katell Le Lay, Charles Taieb, Marco Matucci-Cerinic.   

Abstract

OBJECTIVE: A survey was performed in 5 European countries (France, Germany, Italy, Portugal, and Spain) to estimate the prevalence of fibromyalgia (FM) in the general population.
METHODS: In each country, the London Fibromyalgia Epidemiological Study Screening Questionnaire (LFESSQ) was administered by telephone to a representative sample of the community over 15 years of age. A positive screen was defined as the following: (1) meeting the 4-pain criteria alone (LFESSQ-4), or (2) meeting both the 4-pain and the 2-fatigue criteria (LFESSQ-6). The questionnaire was also submitted to all outpatients referred to the 8 participating rheumatology clinics for 1 month. These patients were examined by a rheumatologist to confirm or exclude the FM diagnosis according to the 1990 American College of Rheumatology classification criteria. The prevalence of FM in the general population was estimated by applying the positive-predictive values to eligible community subjects (ie, positive screens).
RESULTS: Among rheumatology outpatients, 46% screened positive for chronic widespread pain (LFESSQ-4), 32% for pain and fatigue (LFESSQ-6), and 14% were confirmed FM cases. In the whole general population, 13 and 6.7% screened positive for LFESSQ-4 and LFESSQ-6, respectively. 3The estimated overall prevalence of FM was 4.7% (95% CI: 4.0 to 5.3) and 2.9% (95% CI: 2.4 to 3.4), respectively, in the general population. The prevalence of FM was age- and sex-related and varied among countries.
CONCLUSION: FM appears to be a common condition in these 5 European countries, even if data derived from the most specific criteria set (LFESSQ-6) are considered. Copyright 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2009        PMID: 19250656     DOI: 10.1016/j.semarthrit.2008.12.003

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  201 in total

1.  Amisulpride in the treatment of fibromyalgia: an uncontrolled study.

Authors:  Fernando Rico-Villademoros; Carmen Maria Rodriguez-Lopez; Piedad Morillas-Arques; Juan S Vilchez; Javier Hidalgo; Elena P Calandre
Journal:  Clin Rheumatol       Date:  2012-06-05       Impact factor: 2.980

Review 2.  Efficacy and safety of meditative movement therapies in fibromyalgia syndrome: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Jost Langhorst; Petra Klose; Gustav J Dobos; Kathrin Bernardy; Winfried Häuser
Journal:  Rheumatol Int       Date:  2012-02-15       Impact factor: 2.631

Review 3.  Worldwide epidemiology of fibromyalgia.

Authors:  Luiz Paulo Queiroz
Journal:  Curr Pain Headache Rep       Date:  2013-08

Review 4.  Fibromyalgia: mechanisms and potential impact of the ACR 2010 classification criteria.

Authors:  John McBeth; Matthew R Mulvey
Journal:  Nat Rev Rheumatol       Date:  2012-01-24       Impact factor: 20.543

5.  Fibromyalgia in patients with other rheumatic diseases: prevalence and relationship with disease activity.

Authors:  Sema Haliloglu; Ayse Carlioglu; Derya Akdeniz; Yasar Karaaslan; Ali Kosar
Journal:  Rheumatol Int       Date:  2014-03-04       Impact factor: 2.631

6.  [Prevalence of chronic pain in Germany. A representative survey of the general population].

Authors:  W Häuser; G Schmutzer; A Hinz; A Hilbert; E Brähler
Journal:  Schmerz       Date:  2013-02       Impact factor: 1.107

7.  Performance of 2016 revised fibromyalgia diagnostic criteria in patients with rheumatoid arthritis.

Authors:  Nada Mahmoud Shresher; Aly Elsayed Mohamed; Mohsen Hassan Elshahaly
Journal:  Rheumatol Int       Date:  2019-08-03       Impact factor: 2.631

Review 8.  Fibromyalgia and chronic widespread pain in autoimmune thyroid disease.

Authors:  Jowairiyya Ahmad; Clement E Tagoe
Journal:  Clin Rheumatol       Date:  2014-01-18       Impact factor: 2.980

9.  Patients' and professionals' views on managing fibromyalgia.

Authors:  Erica Briones-Vozmediano; Carmen Vives-Cases; Elena Ronda-Pérez; Diana Gil-González
Journal:  Pain Res Manag       Date:  2013 Jan-Feb       Impact factor: 3.037

Review 10.  Neurogenic inflammation in fibromyalgia.

Authors:  Geoffrey Littlejohn; Emma Guymer
Journal:  Semin Immunopathol       Date:  2018-03-19       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.